Abnormal hemostasis tests and bleeding in chronic liver disease: Are they related? Yes

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 4, 2006, Pages 717-720

  Reverter, J C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; TRANEXAMIC ACID;

ABDOMINAL SURGERY; ACCURACY; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; CHRONIC LIVER DISEASE; DISEASE SEVERITY; ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; HEMODYNAMIC MONITORING; HUMAN; LAPAROSCOPY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER HEMATOMA; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PORTAL HYPERTENSION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SURVIVAL; THROMBOCYTE COUNT;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; HEMORRHAGE; HEMOSTASIS; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; RISK;

EID: 33644972151     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01887.x     Document Type: Article

References (43)

1. Hedner U, Erhardtsen E. Hemostatic disorders in liver diseases. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins, 2003: 625-36.
2. Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, Mannucci PM. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.
3. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22: 83-96.
4. Green G, Poller L, Thomsen JM, Dymock IW. Factor VII as a marker of hepatocellular synthetic function in liver disease. J Clin Pathol 1976; 29: 971-5.
5. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
6. Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo end-stage liver disease. Hepatology 2001; 33: 473-5.
7. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1: 1504-14.
8. Robert A, Chazouillères O. Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996; 24: 1392-4.
9. Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004; 10: 995-1000.
10. WHO Expert Committee on Biological Standardization. Guideliness for Thromboplastins and Plasma used to Control Oral Anticoagulant Therapy. Technical Report Series 889; 48th report, Geneva, Switzerland, 1999.
11. Joist JH. AICF and DIC in liver cirrhosis: Expressions of a hypercoagulable state. Am J Gastroenterol 1999; 94: 2801-3.
12. Schepis F, Cammà C, Niceforo D, Magnano A, Pallio S, Cinquegrani M, D'amico G, Pasta L, Craxi A, Saitta A, Raimondo G. Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?. Hepatology 2001; 33: 333-8.
13. Zaman A, Hapke R, Flora K, Rosen HR, Benner K. Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am J Gastroenterol 1999; 94: 3292-6.
14. Erlinger S, Benhamou P. Cirrhosis: Clinical aspects. In: McIntyre N, Benhamou JP, Bircher J, Rizzetto M, Rodes J, eds. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1991: 380-90.
15. Friedman LS. The risk of surgery in patients with liver disease. Hepatology 1999; 29: 1617-23.
16. Aranha GV. Cholecystectomy in cirrhotic patients: A formidable operation. Am J Surg 1982; 143: 55-60.
17. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major haemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396-400.
18. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. J Hepatol 1986; 2: 165-73.
19. Ozier Y, Steib A, Ickx B, Nathan N, Derlon A, Guay J, De Moerloose P. Haemostatic disorders during liver transplantation. Eur J Anaesthesiol 2001; 18: 208-18.
20. Escorsell A, Bordas JM, Castaneda B, Llach J, Garcia-Pagan JC, Rodes J, Bosch J. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 1061-7.
21. Dell'era A, Bosch J. Review article: The relevance of portal pressure and other risk factors in acute gastro-oesophageal variceal bleeding. Aliment Pharmacol Ther 2004; 20 (Suppl. 3): 8-15.
22. Boks AL, Brommer EJ, Schalm SW, Van Vliet HH. Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage. Hepatology 1986; 6: 79-86.
23. Bosch J, D'Amico G, García-Pagán JC. Portal hypertension. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of The Liver. Philadelphia: Lippincott Williams & Wilkins, 2003: 429-86.
24. Lisman T, Leebeek FW, Meijer K, Van Der Meer J, Nieuwenhuis HK, De Groot PG. Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 2002; 35: 616-21.
25. Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez Abraldes J, Fabricius S, Erhardtsen E, de Franchis R; European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial. Gastroenterology 2004; 127: 1123-30.
26. Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, Palareti G, Hermans J, Terpstra OT. Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomized double-blind study. EMSALT Study Group. Lancet 2000; 355: 1303-9.
27. Dalmau A, Sabate A, Acosta F, Garcia-Huete L, Koo M, Sansano T, Rafecas A, Figueras J, Jaurrieta E, Parrilla P. Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 2000; 91: 29-34.
28. Piscaglia F, Siringo S, Hermida RC, Legnani C, Valgimigli M, Donati G, Palareti G, Gramantieri L, Gaiani S, Burroughs AK, Bolondi L. Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology 2000; 31: 349-57.
29. Violi F, Basili S, Ferro D, Quintarelli C, Alessandril C, Cordova C. Association between high values of D-dimer and tissue-plasminogen activator activity and first gastrointestinal bleeding in cirrhotic patients. Thromb Hemost 1996; 76: 177-83.
30. Francis RB, Jr., Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984; 14: 460-5.
31. Bosch J, Reverter JC. The coagulopathy of cirrhosis: Myth or reality? Hepatology 2005; 41: 434-5.
32. Nidegger D, Ragot S, Berthelemy P, Masliah C, Pilette C, Martin T, Bianchi A, Paupard T, Silvain C, Beauchant M. Cirrhosis and bleeding: the need for very early management. J Hepatol 2003; 39: 509-14.
33. Patch D, Armonis A, Sabin C, Christopoulou K, Greenslade L, McCormick A, Dick R, Burroughs AK. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. Gut 1999; 44: 264-9.
34. Lecleire S, Di Fiore F, Merle V, Herve S, Duhamel C, Rudelli A, Nousbaum JB, Amouretti M, Dupas JL, Gouerou H, Czernichow P, Lerebours E. Acute upper gastrointestinal bleeding in patients with liver cirrhosis and in noncirrhotic patients: Epidemiology and predictive factors of mortality in a prospective multicenter population-based study. J Clin Gastroenterol 2005; 39: 321-7.
35. Garrison RN, Cryer HM, Howard DA, Polk HC Jr. Clarification of risk factor for abdominal operations in patients with hepatic cirrhosis. Ann Surg 1984; 199: 648-55.
36. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-70.
37. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: An audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437-41.
38. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981; 26: 388-93.
39. Bonnard P, Vitte RL, Barbare JC, Denis J, Stepani P, Di Martino V, Coutarel P, Eugene C, Van Batten C, Cadranel JF. Is bleeding time measurement useful for choosing the liver biopsy route? The results of a pragmatic, prospective multicentric study in 219 patients. J Clin Gastroenterol 1999; 29: 347-9.
40. Schiff J, Misra M, Rendon G, Rothschild J, Schwaitzberg S. Laparoscopic cholecystectomy in cirrhotic patients. Surg Endosc 2005; 19: 1278-81.
41. Steib A, Freys G, Lehmann C, Meyer C, Mahoudeau G. Intraoperative blood losses and transfusion requirements during adult liver transplantation remain difficult to predict. Can J Anaesth 2001; 48: 1075-9.
42. Escolar G, Cases A, Viñas M, Pino M, Calls J, Cirera I, Ordinas A. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): Influence of hematocrit elevation. Haematologica 1999; 84: 614-9.
43. Fricke W, Kouides P, Kessler C, Schmaier AH, Krijanovski Y, Jagadeesan K, Joist J. A multicenter clinical evaluation of the Clot Signature Analyzer. J Thromb Haemost 2004; 2: 763-8.